J&J COVID-19 vaccine pause to be reviewed by U.S. panel next week
Reuters
Published Apr 16, 2021 02:54PM ET
By Manas Mishra and Carl O'Donnell
(Reuters) - A U.S. panel will meet again next week to discuss whether the pause on the use of Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine should continue, after delaying a vote on the matter earlier this week.
The U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on April 23, a top U.S. health official said on Friday.
The continued pause "will allow additional time to review any additional cases that might come in, and for (the panel) to conduct a complete risk assessment and to evaluate the emerging science," CDC Director Dr. Rochelle Walensky said during a Friday news conference.
U.S. health regulators recommended earlier this week that use of the J&J vaccine be paused after reports of six cases of rare brain blood clots in women, out of some 7 million people who have received the shot in the United States.
The advisory panel on Wednesday called for more data before making a decision on how and whether to resume use of the one-shot vaccine.
Walensky said supply of COVID-19 vaccines from Moderna (NASDAQ:MRNA) Inc and Pfizer Inc (NYSE:PFE) will remain strong, even as administering of J&J's vaccine remains on hold.
"We continue to work with pharmacies, states and FEMA (the Federal Emergency Management Agency) to make sure the vaccine supply remains robust across the country," she said.
Reuters reported on Friday that rich countries are stocking up on Pfizer/BioNTech and Moderna shots as concerns mount about vaccines from J&J and AstraZeneca (NASDAQ:AZN) Plc.
Walensky said she is very concerned about rising U.S. COVID-19 cases driven by the relaxing of state restrictions to curb virus transmission and the spread of more contagious new coronavirus variants of COVID-19.
The U.S. seven-day average daily case count is 69,500, with hospitalizations up 5% to 8%, and daily deaths have increased for the third day in a row, Walensky added.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.